Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dutogliptin plus Filgrastim in Early Recovery Post-MI
NCT03486080Phase 2Completed
- Sponsor
- Recardio Inc.
- Start
- Dec 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in ST elevation myocardial infarction (STEMI) comparing Dutogliptin/filgrastim combination with Placebo control (2 arms). Primary endpoint: Safety assessment of the number of Grade 3 and 4 treatment emergent AEs or serious AEs (SAEs) at 90 days. Started Dec 2018; status: completed.
02
Drugs
dutogliptin
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT03486080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03486080.